Other Intangible Assets, Net (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended				12 Months Ended		12 Months Ended						12 Months Ended
	Dec. 31, 2011 Y	Dec. 31, 2010	Dec. 31, 2009	Oct. 12, 2010 Movetis	Dec. 31, 2010 Currently Marketed Products Y	Dec. 31, 2011 Currently Marketed Products	Dec. 31, 2011 Currently Marketed Products ABH Y	Dec. 31, 2010 Currently Marketed Products Movetis	Dec. 31, 2011 Acquired Product Technology	Dec. 31, 2010 Acquired Product Technology	Dec. 31, 2011 Other Intangible Assets	Dec. 31, 2010 Other Intangible Assets	Dec. 31, 2011 IPR&D	Dec. 31, 2010 IPR&D	Dec. 31, 2011 Regenerative Medicine	Dec. 31, 2010 Regenerative Medicine	Dec. 31, 2011 Specialty Pharmaceuticals	Dec. 31, 2010 Specialty Pharmaceuticals	Dec. 31, 2010 Specialty Pharmaceuticals IPR&D Movetis	Dec. 31, 2011 Human Genetic Therapies	Dec. 31, 2010 Human Genetic Therapies
Intangible Assets (Excluding Goodwill) [Line Items]
Amortized intangible assets	$ 3,233.9	$ 2,538.4			$ 2,516.4	$ 2,500.7			$ 710.0	$ 0	$ 23.2	$ 22.0
Uamortized intangible assets													119.8	139.7
Other intangible assets, gross	3,353.7	2,678.1
Less: Accumulated amortization	(860.7)	(699.2)
Other intangible assets, net	2,493.0	1,978.9	1,790.7												691.5	0	1,348.3	1,482.9		453.2	496.0
Other Disclosures
Acquired intangible assets	717.1	472.7						317.0
IPR&D				139.0															139.0
Weighted average amortization period of acquired amortizable intangible assets (in years)	16.5				14		18
Impairment of intangible assets	16.0	42.7	0										16.0	0
Estimated future intangible assets amortization charge - Year 1	190
Estimated future intangible assets amortization charge - Year 2	190
Estimated future intangible assets amortization charge - Year 3	190
Estimated future intangible assets amortization charge - Year 4	190
Estimated future intangible assets amortization charge - Year 5	$ 190